The Cheapest Place to Learn Your Plan Doesn’t Work.
Q-Sub strategy — Pre-Submissions above all — run as decision meetings that produce written FDA feedback while your program still has options.
The Q-Submission Program Is a Family. Most Teams Know One Member.
Each request type answers a different question. Choosing the right one is the first piece of strategy — and the one most often skipped.
Pre-Submission
Written FDA feedback on specific questions about a planned submission — testing plans, clinical protocols, predicate logic, pathway choice.
Study Risk Determination
FDA’s written call on whether a planned device study is significant risk or nonsignificant risk.
Informal Feedback & 513(g)
Lighter-touch feedback, or a formal 513(g) request for FDA’s view on classification and the regulatory requirements that apply.
Submission Issue Request
A meeting to work through a hold or deficiency on a submission already under review — when correspondence has stopped converging.
Agreement & Determination Meetings
The statutory meetings for IDE studies — agreement on an investigational plan, or a determination on the evidence a PMA will require.
The One You Skipped
The most expensive Q-Sub is the one never filed — discovered as a deficiency letter that asks a question you could have asked first.
Plan for the calendar, not the meeting.
FDA’s Q-Sub guidance sets a goal of feedback within 70 days, or a meeting within 75 days, of receipt. That is a quarter of runway — which is why Q-Subs belong in the program plan from the start, not wedged in when a question becomes urgent.
A Good Question Gets a Useful Answer. A Vague One Gets a Reminder.
The single determinant of Q-Sub value is question quality. The work happens before the meeting: the briefing package has to present your position, your evidence, and your specific ask — because FDA’s feedback tracks what you gave them.
A Q-Sub is not a conversation you attend. It is a document you write, with a meeting attached.
Reviewers form their positions while reading. What happens in the room mostly confirms what the briefing document earned.
“Does FDA agree with our approach?”
Invites a restatement of the guidance you already have. Nothing is decided; the reviewer has been given no position to accept or reject.
“We propose this test matrix for these three differences from our predicate. Does the Agency agree it addresses the new questions raised by the change in material?”
Your position, the evidence, and a specific ask — so agreement means something you can build on and cite in the submission.
Six Disciplines That Make a Q-Sub Worth the Quarter.
From choosing the request type to holding FDA’s feedback in the record afterward.
Request-Type Strategy
The right member of the Q-Sub family for the question you actually have — and the honest call when the answer is “none, file the submission.”
Question Architecture
Questions engineered to be answerable: your position stated, the alternative named, the ask specific enough that agreement means something.
Briefing Package Build
The document that does the persuading — device description, the decision at issue, the evidence, and the proposal, in the reviewer’s order.
Meeting Execution
The team prepared, the roles assigned, and the difficult questions rehearsed — so the meeting closes decisions instead of opening topics.
Minutes & Record Discipline
Your minutes submitted, FDA’s feedback preserved, and the commitments documented — the record you will cite in your submission two years later.
Q-Sub Sequencing
Interactions mapped across the program — pathway, then evidence plan, then protocol — instead of one panicked meeting when a deficiency lands.
Six Failure Modes We Are Brought In to Prevent.
A wasted Q-Sub costs a quarter and teaches the review team that you don’t come prepared.
Questions that can only be answered “it depends”
Open-ended asks that invite a recitation of guidance — a quarter spent to receive the document you already had.
No position of your own
Presenting options without a recommendation. Reviewers respond to proposals; they rarely design your program for you.
Too many questions
A briefing package with fourteen asks gets fourteen shallow answers — and none on the question that mattered.
The meeting nobody prepared for
A team that hasn’t rehearsed, contradicting itself in front of the review division — a credibility cost that outlives the meeting.
Feedback that isn’t captured
Minutes never submitted, commitments never documented — and an understanding that evaporates when the reviewer changes.
Feedback treated as permission
Non-binding agreement carried into a submission whose facts have since drifted — and a reviewer entitled to revisit all of it.
Q-Sub Leadership That Comes With a Position.
Our device leads have written the packages, chaired the meetings, and held the record afterward.
“Never ask FDA what to do. Tell them what you intend to do, show why, and ask whether they agree. That is the difference between feedback and a lecture.”
The discipline we bring to every agency interaction.
Have a Question for FDA? Make It One They Can Answer.
A senior lead can shape the request type, the questions, and the package — so the quarter you spend waiting buys a decision.
Senior-led. Embedded in your team. No junior hand-offs.